| Name | Title | Contact Details |
|---|
Liverpool Football Club was founded in 1892 and is one of the worlds most historic and famous football clubs. Honours include 19 League Titles, eight FA Cups, ten League Cups, six European Cups, three UEFA Cups, four European Super Cups, 16 Charity Shields, one FIFA Club World Cup, two Womens Super League and one Womens Championship. As a socially responsible club, Liverpool FC is proud of its heritage and plays a proactive role in its communities through its official charity, Liverpool FC Foundation, which helps children and families in Merseyside and beyond, and the Red Neighbours programme, which creates events and experiences specifically aimed at improving the lives of those living in and around the Anfield area (L4, L5 and L6). Liverpool FC is a global brand and works with leading edge commercial partners around the world providing unparalleled commercial opportunities.
Payfare is a global FinTech company offering mobile banking, instant payment and loyalty-reward solutions for today`s workforce. Payfare`s financial technology platform is providing financial inclusion and empowerment to millions of next-generation workers around the globe with a full-service mobile bank account and debit card with instant access to their earnings and relevant cash-back rewards. Payfare was founded in 2015 by fintech entrepreneurs and a senior management team with unparalleled experience in the banking, payment card and financial technology sectors. Payfare is backed by major investors and financial institutions around the world. The company is headquartered in Toronto, Canada. Some of the world`s largest on-demand economy platforms including Uber, Lyft, DoorDash and DiDi trust Payfare to pay their workers.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.